Stoke Therapeutics, Inc. STOK NASDAQ

Stoke Therapeutics, Inc. (STOK) has a negative trailing P/E of -298.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 434.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.34%, forward earnings yield 0.23%. PEG 0.21 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

• VALUE (35/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -298.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -0.34%).
• Forward P/E 434.7 — analysts expect a return to profitability with estimated EPS of $0.08 for FY2029.
• PEG Ratio 0.21 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
• Trailing Earnings Yield -0.34% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.23% as earnings recover.
• Analyst consensus target $42.75 (+19.2% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 53/100 with 3/7 criteria passed.